 |
SYDNEY, June 30, 2021/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide an update on recent progress with its two pipeline assets, paxalisib and EVT801.
Key Points
While it was inconceivable to have a game room in any office space until just a decade or two ago, such designated spaces are now quite common and...
Australia’s leading online book retailer Booktopia Group Limited (ASX: BKG) (“the Company”) is pleased to announce it has finalised a $12 million f...
As an employer or entrepreneur, you know that your business success depends on your team's productivity, efficiency, and satisfaction. But did you k...
In recent years, mortgage brokers have taken on a significant role in shaping the Australian housing market. With their expertise and access to a wi...
Graphic design has come a long way since its inception, and the tools available today drastically differ from those used in decades past. As techn...
Pursuing a Master of Business Administration (MBA) degree is a significant decision that requires careful planning and preparation. As the competi...